Subscribe to RSS
DOI: 10.1055/s-0042-122783
Parthenolide Modulates Immune Response in Cells from C57BL/6 Mice Induced with Experimental Autoimmune Encephalomyelitis
Publication History
received 20 July 2016
revised 21 November 2016
accepted 25 November 2016
Publication Date:
20 December 2016 (online)
![](https://www.thieme-connect.de/media/plantamedica/201708/lookinside/thumbnails/10-1055-s-0042-122783_pma0592-1.jpg)
Abstract
Multiple sclerosis is a chronic inflammatory and autoimmune disease of the central nervous system that affects more than 2.5 million people worldwide. Experimental autoimmune encephalomyelitis is a murine autoimmune disease used to study multiple sclerosis. Parthenolide, a natural sesquiterpene lactone found in Tanacetum parthenium L., is known for its strong anti-inflammatory activity. Herein, we have investigated the in vitro immunomodulatory effects of parthenolide on cytokine production and nitric oxide in cultured cells from myelin oligodendrocyte glycoprotein 35–55 amino acid peptide mice. Experimental autoimmune encephalomyelitis was induced in C57BL/6 mice with myelin oligodendrocyte glycoprotein 35–55 amino acid peptide, and parthenolide was isolated from T. parthenium. Splenocytes and peritoneal cells were obtained from experimental autoimmune encephalomyelitis-induced mice and incubated with parthenolide (1, 5, and 20 µM). After in vitro treatment with parthenolide, supernatants were collected, and nitric oxide and cytokines were measured. The results suggested that parthenolide may regulate the activity of Th17 and Th1 cells, mainly by decreasing IL-17, TNF-α, and interferon gamma production. This modulation may be related to the lower levels of IL-12p40 and IL-6 after treatment with parthenolide. It was shown, for the first time, that parthenolide presents in vitro immunomodulatory effects on inflammatory mediators produced by cells from experimental autoimmune encephalomyelitis-induced mice.
-
References
- 1 Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-955
- 2 Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-952
- 3 Shen R, Deng W, Li C, Zeng G. A natural flavonoid glucoside icariin inhibits Th1 and Th17 cell differentiation and ameliorates experimental autoimmune encephalomyelitis. Int Immunopharmacol 2015; 24: 224-231
- 4 Dutra RC, De Souza PRC, Bento AF, Marcon R, Bicca MA, Pianowski LF, Calixto JB. Euphol prevents experimental autoimmune encephalomyelitis in mice: evidence for the underlying mechanisms. Biochem Pharmacol 2012; 83: 531-542
- 5 Constantinescu CS, Farooqi N, OʼBrien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 2011; 164: 1079-1106
- 6 Fontes LBA, Dias DS, De Carvalho LSA, Mesquita HL, Reis LS, Dias AT, Da Silva Filho AA, Corrêa JOA. Immunomodulatory effects of licochalcone A on experimental autoimmune encephalomyelitis. J Pharm Pharmacol 2014; 66: 886-894
- 7 Dias DS, Fontes LBA, Crotti AEM, Aarestrup BJV, Aarestrup FM, Da Silva Filho AA, Corrêa JOA. Copaiba oil suppresses inflammatory cytokines in splenocytes of C57BL/6 mice induced with experimental autoimmune encephalomyelitis (EAE). Molecules 2014; 19: 12814-12826
- 8 Qin X, Guo BT, Wan B, Fang L, Lu L, Wu L, Zang YQ, Zhang JZ. Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine. J Immunol 2010; 185: 1855-1863
- 9 Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn Rev 2011; 5: 103-110
- 10 Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 1992; 43: 2313-2320
- 11 Zhao ZJ, Xiang JY, Liu L, Huang XL, Gan HT. Parthenolide, an inhibitor of the nuclear factor-kB pathway, ameliorates dextran sulfate sodium-induced colitis in mice. Int Immunopharmacol 2012; 12: 169-174
- 12 Magni P, Ruscica M, Dozio E, Rizzi E, Beretta G, Facino RM. Parthenolide inhibits the LPS-induced secretion of IL-6 and TNF-α and NF-kB nuclear translocation in BV-2 microglia. Phytother Res 2012; 26: 1405-1409
- 13 Kwok BHB, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IκB kinase. Chem Biol 2001; 8: 759-766
- 14 Carlisi D, DʼAnneo A, Angileri L, Lauricella M, Emanuele S, Santulli A, Vento R, Tesoriere G. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol 2011; 226: 1632-1641
- 15 Orhan IE, Tosun F, Lpinar ARG, Kartal M, Duran A, Mihoglugil F, Akalgan D. LC–MS quantification of parthenolide and cholinesterase inhibitory potential of selected Tanacetum L. (Emend. Briq.) taxa. Phytochem Lett 2015; 11: 347-352
- 16 Kim SL, Kim SH, Trang KTT, Kim IH, Lee SO, Lee ST, Kim DG, Kang SB, Kim SW. Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. Cancer Lett 2013; 335: 479-486
- 17 Ku C, Lin J. Anti-inflammatory effects of 27 selected terpenoids compounds tested through modulating Th1/Th2 cytokine secretion profiles using murine primary splenocytes. Food Chem 2013; 141: 1104-1113
- 18 Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170: 607-612
- 19 Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 1173-1175
- 20 Murphy AC, Lalor SJ, Lynch MA, Mills KHG. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 2010; 24: 641-651
- 21 Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 566-573
- 22 Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006; 36: 2868-2874
- 23 Gijbels K, Brocke S, Abrams JS, Steinman L. Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol Med 1995; 1: 795-805
- 24 Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8: 967-974
- 25 Liu N, Kan QC, Zhang XJ, Xv YM, Zhang S, Zhang GX, Zhu L. Upregulation of immunomodulatory molecules by matrine treatment inexperimental autoimmune encephalomyelitis. Exp Mol Pathol 2014; 97: 470-476
- 26 Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor 0, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992; 176: 1355-1364
- 27 Muramatsu R, Kubo T, Mori M, Nakamura Y, Fujita Y, Akutsu T, Okuno T, Taniguchi J, Kumanogoh A, Yoshida M, Mochizuki H, Kuwabara S, Yamashita T. RGMa modulates T cell responses and is involved in autoimmune encephalomyelitis. Nat Med 2011; 17: 488-494
- 28 Li-Weber M, Giaisi M, Treiber MK, Krammer PH. The anti-inflammatory sesquiterpene lactone parthenolide suppresses IL-4 gene expression in peripheral blood T cells. Eur J Immunol 2002; 32: 3587-3597
- 29 Falcone M, Rajan AJ, Bloom BR, Brosnan CF. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J Immunol 1998; 160: 4822-4830
- 30 Dey S, Sarkar M, Giri B. Anti-inflammatory and anti-tumor activities of parthenolide: an update. J Chem Biol Ther 2016; 2: 1-6
- 31 OʼNeill LA, Barrett ML, Lewis GP. Extracts of feverfew inhibit mitogen-induced human peripheral blood mononuclear cell proliferation and cytokine mediated responses: a cytotoxic effect. Br J Clin Pharmacol 1987; 23: 81-83
- 32 Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007; 117: 1119-1127
- 33 Zhang J, Benedek G, Bodhankar S, Lapato A, Vandenbark AA, Offner H. IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice. J Neuroimmunol 2015; 285: 129-136
- 34 Kang BY, Chung SW, Kim TS. Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by parthenolide, a predominant sesquiterpene lactone in Tanacetum parthenium: involvement of nuclear factor-kappaB. Immunol Lett 2001; 77: 159-163
- 35 Uchi H, Arrighi JF, Aubry JP, Furue M, Hauser C. The sesquiterpene lactone parthenolide inhibits LPS- but not TNF-alpha-induced maturation of human monocyte-derived dendritic cells by inhibition of the p38 mitogen-activated protein kinase pathway. J Allergy Clin Immunol 2002; 110: 269-276
- 36 Brok HPM, Van Meurs M, Blezer E, Schantz A, Peritt D, Treacy G, Laman JD, Bauer J, Hart BA. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 2002; 169: 6554-6563
- 37 Gran B, Zhang GX, Yu S, Li J, Chen XH, Ventura ES, Kamoun M, Rostami A. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002; 169: 7104-7110
- 38 Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116: 1218-1222
- 39 Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H. Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010; 23: 75-93
- 40 Leiper J, Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov 2011; 10: 277-291
- 41 Ljubisavljevic S, Stojanovic I, Pavlovic R, Sokolovic D, Pavlovic D, Cvetkovic T, Stevanovic I. Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis. J Neurol Sci 2012; 318: 106-111
- 42 Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994; 93: 2684-2690
- 43 Fukuda K, Hibiya Y, Mutoh M, Ohno Y, Yamashita K, Akao S, Fujiwara H. Inhibition by parthenolide of phorbol ester-induced transcriptional activation of inducible nitric oxide synthase gene in a human monocyte cell line THP-1. Biochem Pharmacol 2000; 60: 595-600
- 44 Fiebich BL, Lieb K, Engels S, Heinrich M. Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. J Neuroimmunol 2002; 132: 18-24
- 45 Herrera F, Martin V, Rodriguez-Blanco J, García-Santos G, Antolín I, Rodriguez C. Intracellular redox state regulation by parthenolide. Biochem Biophys Res Commun 2005; 332: 321-325
- 46 Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15 N] nitrate in biological fluids. Anal Biochem 1982; 126: 131-138